NDAINTRAVENOUSEMULSION
Approved
Sep 2022
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
5/8 — Partial
APONVIE (aprepitant) by Heron Therapeutics is neurokinin 1 antagonists [moa]. First approved in 2022.
Drug data last refreshed 3h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
APONVIE (aprepitant) is an intravenous neurokinin-1 receptor antagonist formulated as an emulsion, approved in September 2022 by Heron Therapeutics. It blocks substance P signaling in the central nervous system to prevent chemotherapy-induced nausea and vomiting (CINV). The IV emulsion formulation represents a novel delivery approach for an established mechanism of action.
Peak8.9 years to LOE
Product is in peak lifecycle stage approximately 4 years post-launch; commercial team likely stabilized but focused on market penetration and indication expansion.
Mechanism of Action
Neurokinin 1 Antagonists
Pharmacologic Class:
Substance P/Neurokinin-1 Receptor Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Aprepitant to Improve Same Day Discharge for TKA
Started Jul 2026
350 enrolled
PONV
Efficacy and Safety Study of Aprepitant Injection for Prevention of Post-operative Nausea and Vomiting
Started Feb 2024
518 enrolled
Postoperative Nausea and Vomiting
Aprepitant Injectable Emulsion in Patients With COVID-19 (GUARDS-1)
Started Jul 2020
27 enrolled
COVID-19
Safety of a Three-Day Fosaprepitant Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-045)
Started Sep 2019
103 enrolled
Chemotherapy-induced Nausea and Vomiting
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
Started Nov 2018
690 enrolled
Malignant Neoplasm
Worked on APONVIE at Heron Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.